<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856647</url>
  </required_header>
  <id_info>
    <org_study_id>JUG-0799</org_study_id>
    <nct_id>NCT01856647</nct_id>
  </id_info>
  <brief_title>Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects</brief_title>
  <official_title>A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and&#xD;
      risk factor for type 2 diabetes and the metabolic syndrome, often linked to cardiovascular&#xD;
      disease, certain cancers and inflammatory diseases.The phenotyping of subcutaneous adipose&#xD;
      tissue (SAT) hematopoetic cells from obese subjects by flow cytometry, microscopy and gene&#xD;
      expression will enable us to identify inflammation in this tissue and may help us to&#xD;
      understand the causes and consequences of obesity in order to determine how these cells might&#xD;
      be implicated in the initiation and/or progression of the aforementioned diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and&#xD;
      risk factor for type 2 diabetes and the metabolic syndrome. It is also often linked to&#xD;
      cardiovascular disease, certain cancers (e.g., colorectal, esophageal, endometrial, and&#xD;
      ovarian), and inflammatory diseases (e.g., psoriasis, osteoarthritis,inflammatory bowel&#xD;
      disease).The phenotyping of subcutaneous adipose tissue (SAT) hematopoetic cells from obese&#xD;
      subjects by flow cytometry, microscopy and gene expression will enable us to identify&#xD;
      inflammation in this tissue and may help us to understand the causes and consequences of&#xD;
      obesity in order to determine how these cells might be implicated in the initiation and/or&#xD;
      progression of the aforementioned diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers for phenotyping a new type of leukocyte</measure>
    <time_frame>5 years</time_frame>
    <description>Biomarkers for phenotyping a new type of leukocyte</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Psoriasis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>lean (BMI≤ 24.9 Kg/m2)</arm_group_label>
    <description>Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese (BMI= 30-40 Kg/m2)</arm_group_label>
    <description>9 obese (BMI= 30-40 Kg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriatic lean</arm_group_label>
    <description>9 psoriatic lean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriatic obese</arm_group_label>
    <description>9 psoriatic obese</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adipose tissue biopsy (fat biopsy)</intervention_name>
    <description>An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.</description>
    <arm_group_label>lean (BMI≤ 24.9 Kg/m2)</arm_group_label>
    <arm_group_label>obese (BMI= 30-40 Kg/m2)</arm_group_label>
    <arm_group_label>psoriatic lean</arm_group_label>
    <arm_group_label>psoriatic obese</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fat Biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obesity and psoriasis are characterized by infiltration of inflammatory cells (leukocytes)&#xD;
        in SAT and skin, respectively. We expect that SAT in obese psoriasis subjects will have&#xD;
        infiltrating inflammatory leukocytes because of obesity, and that these infiltrating&#xD;
        leukocytes might be different and/or increased in numbers by the pathology of psoriasis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Psoriatic lean cohort (BMI between 18-24.9 Kg/m2): moderate to severe plaque-type, at&#xD;
             least 5% of BSA&#xD;
&#xD;
          -  Psoriatic obese cohort (BMI between 30-40 Kg/m2): moderate to severe plaque-type, at&#xD;
             least 5% of BSA&#xD;
&#xD;
          -  Lean/non-psoriatic cohort: BMI between 18-24.9 Kg/m2&#xD;
&#xD;
          -  Overweight/obese non-psoriatic cohort: BMI between 30-40 Kg/m2&#xD;
&#xD;
          -  Subjects must be 18-65 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having received any systemic treatment for psoriasis within the last 30 days&#xD;
&#xD;
          -  history of bleeding disorder&#xD;
&#xD;
          -  weight loss of 10 pounds in the last four weeks&#xD;
&#xD;
          -  current smoker&#xD;
&#xD;
          -  Known diagnosis of any unrelated autoimmune disease or inflammatory disease ( i.e.&#xD;
             lupus, atopic dermatitis, rheumatoid arthritis).&#xD;
&#xD;
          -  Currently taking NSAIDS, aspirin, (if &gt; once a week, stopped &lt;30 days ago). Aspirin&#xD;
             81mg may be permitted if the Framingham Risk Score is &lt; 10&#xD;
&#xD;
          -  Having received any anti-inflammatory medication within the last 30 days&#xD;
&#xD;
          -  Current use of any anti-coagulants&#xD;
&#xD;
          -  LFTs &gt; 2 x upper normal limits&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Less than 6 weeks post partum&#xD;
&#xD;
          -  history of cardiovascular disease (MI, CHF, CVA)&#xD;
&#xD;
          -  Any cancer diagnosis within the last 5 years&#xD;
&#xD;
          -  Symptoms of acute illness such as upper respiratory infection, bronchitis,&#xD;
             gastroenteritis, or fever within 3 days of Visit 1&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data&#xD;
&#xD;
          -  ingestion of DHA or fish oil within last 90 days&#xD;
&#xD;
          -  hypertension as defined as &gt; 140 systolic and &gt; 90 diastolic after 10 minutes of&#xD;
             resting on 2 antihypertensives&#xD;
&#xD;
          -  Use of statins within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juana Gonzalez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller Univesrity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>December 18, 2015</last_update_submitted>
  <last_update_submitted_qc>December 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

